Table of Contents

2019-2024 Global Gefitinib Consumption Market Report

1 Scope of the Report

• 1.1 Market Introduction
• 1.2 Research Objectives
• 1.3 Years Considered
• 1.4 Market Research Methodology
• 1.5 Economic Indicators
• 1.6 Currency Considered

2 Executive Summary

• 2.1 World Market Overview
  • 2.1.1 Global Gefitinib Consumption 2014-2024
  • 2.1.2 Gefitinib Consumption CAGR by Region
• 2.2 Gefitinib Segment by Type
  • 2.2.1 10 Tables/Box
  • 2.2.2 30 Tables/Box
  • 2.2.3 90 Tables/Box
• 2.3 Gefitinib Consumption by Type
  • 2.3.1 Global Gefitinib Consumption Market Share by Type (2014-2019)
  • 2.3.2 Global Gefitinib Revenue and Market Share by Type (2014-2019)
  • 2.3.3 Global Gefitinib Sale Price by Type (2014-2019)
• 2.4 Gefitinib Segment by Application
  • 2.4.1 Hospital
  • 2.4.2 Clinic
  • 2.4.3 Drug Center
  • 2.4.4 Other
• 2.5 Gefitinib Consumption by Application
  • 2.5.1 Global Gefitinib Consumption Market Share by Application (2014-2019)
  • 2.5.2 Global Gefitinib Value and Market Share by Application (2014-2019)
  • 2.5.3 Global Gefitinib Sale Price by Application (2014-2019)

3 Global Gefitinib by Manufacturers

• 3.1 Global Gefitinib Sales Market Share by Manufacturers
  • 3.1.1 Global Gefitinib Sales by Manufacturers (2017-2019)
  • 3.1.2 Global Gefitinib Sales Market Share by Manufacturers (2017-2019)
• 3.2 Global Gefitinib Revenue Market Share by Manufacturers
  • 3.2.1 Global Gefitinib Revenue by Manufacturers (2017-2019)
  • 3.2.2 Global Gefitinib Revenue Market Share by Manufacturers (2017-2019)
• 3.3 Global Gefitinib Sale Price by Manufacturers
• 3.4 Global Gefitinib Manufacturing Base Distribution, Sales Area, Product Types by Manufacturers
  • 3.4.1 Global Gefitinib Manufacturing Base Distribution and Sales Area by Manufacturers
  • 3.4.2 Players Gefitinib Products Offered
• 3.5 Market Concentration Rate Analysis
  • 3.5.1 Competition Landscape Analysis
  • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
• 3.6 New Products and Potential Entrants
• 3.7 Mergers & Acquisitions, Expansion

4 Gefitinib by Regions

• 4.1 Gefitinib by Regions
  • 4.1.1 Global Gefitinib Consumption by Regions
  • 4.1.2 Global Gefitinib Value by Regions
• 4.2 Americas Gefitinib Consumption Growth
• 4.3 APAC Gefitinib Consumption Growth
• 4.4 Europe Gefitinib Consumption Growth
• 4.5 Middle East & Africa Gefitinib Consumption Growth

5 Americas

• 5.1 Americas Gefitinib Consumption by Countries
  • 5.1.1 Americas Gefitinib Consumption by Countries (2014-2019)
  • 5.1.2 Americas Gefitinib Value by Countries (2014-2019)
• 5.2 Americas Gefitinib Consumption by Type
• 5.3 Americas Gefitinib Consumption by Application
• 5.4 United States
• 5.5 Canada
• 5.6 Mexico
• 5.7 Key Economic Indicators of Few Americas Countries

6 APAC

• 6.1 APAC Gefitinib Consumption by Countries
  • 6.1.1 APAC Gefitinib Consumption by Countries (2014-2019)
  • 6.1.2 APAC Gefitinib Value by Countries (2014-2019)
• 6.2 APAC Gefitinib Consumption by Type
• 6.3 APAC Gefitinib Consumption by Application
• 6.4 China
• 6.5 Japan
• 6.6 Korea
• 6.7 Southeast Asia
• 6.8 India
• 6.9 Australia
• 6.10 Key Economic Indicators of Few APAC Countries

7 Europe

• 7.1 Europe Gefitinib by Countries
  • 7.1.1 Europe Gefitinib Consumption by Countries (2014-2019)
  • 7.1.2 Europe Gefitinib Value by Countries (2014-2019)
• 7.2 Europe Gefitinib Consumption by Type
• 7.3 Europe Gefitinib Consumption by Application
• 7.4 Germany
• 7.5 France
• 7.6 UK
• 7.7 Italy
• 7.8 Russia
• 7.9 Spain
• 7.10 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa

• 8.1 Middle East & Africa Gefitinib by Countries
  • 8.1.1 Middle East & Africa Gefitinib Consumption by Countries (2014-2019)
  • 8.1.2 Middle East & Africa Gefitinib Value by Countries (2014-2019)
• 8.2 Middle East & Africa Gefitinib Consumption by Type
• 8.3 Middle East & Africa Gefitinib Consumption by Application
• 8.4 Egypt
• 8.5 South Africa
• 8.6 Israel
• 8.7 Turkey
• 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

• 9.1 Market Drivers and Impact
  • 9.1.1 Growing Demand from Key Regions
  • 9.1.2 Growing Demand from Key Applications and Potential Industries
• 9.2 Market Challenges and Impact
• 9.3 Market Trends

10 Marketing, Distributors and Customer

• 10.1 Sales Channel
  • 10.1.1 Direct Channels
  • 10.1.2 Indirect Channels
• 10.2 Gefitinib Distributors
• 10.3 Gefitinib Customer

11 Global Gefitinib Market Forecast

• 11.1 Global Gefitinib Consumption Forecast (2019-2024)
• 11.2 Global Gefitinib Forecast by Regions
  • 11.2.1 Global Gefitinib Forecast by Regions (2019-2024)
  • 11.2.2 Global Gefitinib Value Forecast by Regions (2019-2024)
  • 11.2.3 Americas Consumption Forecast
  • 11.2.4 APAC Consumption Forecast
  • 11.2.5 Europe Consumption Forecast
  • 11.2.6 Middle East & Africa Consumption Forecast
• 11.3 Americas Forecast by Countries
  • 11.3.1 United States Market Forecast
  • 11.3.2 Canada Market Forecast
  • 11.3.3 Mexico Market Forecast
  • 11.3.4 Brazil Market Forecast
• 11.4 APAC Forecast by Countries
  • 11.4.1 China Market Forecast
  • 11.4.2 Japan Market Forecast
  • 11.4.3 Korea Market Forecast
  • 11.4.4 Southeast Asia Market Forecast
  • 11.4.5 India Market Forecast
  • 11.4.6 Australia Market Forecast
• 11.5 Europe Forecast by Countries
  • 11.5.1 Germany Market Forecast
  • 11.5.2 France Market Forecast
  • 11.5.3 UK Market Forecast
  • 11.5.4 Italy Market Forecast
  • 11.5.5 Russia Market Forecast
  • 11.5.6 Spain Market Forecast
• 11.6 Middle East & Africa Forecast by Countries
  • 11.6.1 Egypt Market Forecast
  • 11.6.2 South Africa Market Forecast
  • 11.6.3 Israel Market Forecast
  • 11.6.4 Turkey Market Forecast
  • 11.6.5 GCC Countries Market Forecast
• 11.7 Global Gefitinib Forecast by Type
• 11.8 Global Gefitinib Forecast by Application

12 Key Players Analysis

• 12.1 AstraZeneca
  • 12.1.1 Company Details
  • 12.1.2 Gefitinib Product Offered
  • 12.1.3 AstraZeneca Gefitinib Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.1.4 Main Business Overview
  • 12.1.5 AstraZeneca News
• 12.2 Qilu Pharmaceutical
  • 12.2.1 Company Details
  • 12.2.2 Gefitinib Product Offered
  • 12.2.3 Qilu Pharmaceutical Gefitinib Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.2.4 Main Business Overview
  • 12.2.5 Qilu Pharmaceutical News
• 12.3 Natco Pharma
  • 12.3.1 Company Details
  • 12.3.2 Gefitinib Product Offered
  • 12.3.3 Natco Pharma Gefitinib Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.3.4 Main Business Overview
  • 12.3.5 Natco Pharma News
• 12.4 Celon Laboratories
  • 12.4.1 Company Details
  • 12.4.2 Gefitinib Product Offered
  • 12.4.3 Celon Laboratories Gefitinib Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.4.4 Main Business Overview
  • 12.4.5 Celon Laboratories News
• 12.5 Hetero Drugs
  • 12.5.1 Company Details
  • 12.5.2 Gefitinib Product Offered
  • 12.5.3 Hetero Drugs Gefitinib Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.5.4 Main Business Overview
  • 12.5.5 Hetero Drugs News
• 12.6 Dr Reddy's Laboratories
  • 12.6.1 Company Details
  • 12.6.2 Gefitinib Product Offered
  • 12.6.3 Dr Reddy's Laboratories Gefitinib Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.6.4 Main Business Overview
  • 12.6.5 Dr Reddy's Laboratories News
• 12.7 Zuventus Healthcare
  • 12.7.1 Company Details
  • 12.7.2 Gefitinib Product Offered
  • 12.7.3 Zuventus Healthcare Gefitinib Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.7.4 Main Business Overview
  • 12.7.5 Zuventus Healthcare News
• 12.8 United Biotech
  • 12.8.1 Company Details
  • 12.8.2 Gefitinib Product Offered
  • 12.8.3 United Biotech Gefitinib Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.8.4 Main Business Overview
  • 12.8.5 United Biotech News
• 12.9 Panacea Biotec
  • 12.9.1 Company Details
  • 12.9.2 Gefitinib Product Offered
  • 12.9.3 Panacea Biotec Gefitinib Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.9.4 Main Business Overview
  • 12.9.5 Panacea Biotec News
• 12.10 Cipla
  • 12.10.1 Company Details
  • 12.10.2 Gefitinib Product Offered
  • 12.10.3 Cipla Gefitinib Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.10.4 Main Business Overview
  • 12.10.5 Cipla News
• 12.11 Glenmark Pharmaceuticals
• 12.12 Nobel Ilac Sanayii Ve Ticaret
• 12.13 Accure Labs
• 12.14 Cadila Pharmaceuticals
• 12.15 Ethypharm
• 12.16 Flagship Biotech International
• 12.17 Globela Pharma
• 12.18 Jodas Expoim
• 12.19 Nishchay Pharmaceuticals
• 12.20 Sichuan Xieli Pharmaceutical

13 Research Findings and Conclusion

According to this study, over the next five years the Gefitinib market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Gefitinib business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Gefitinib market by product type, application, key manufacturers and key regions and countries.

This study considers the Gefitinib value and volume generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
10 Tables/Box
30 Tables/Box
90 Tables/Box
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Hospital
Clinic
Drug Center
Other

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
AstraZeneca
Qilu Pharmaceutical
Natco Pharma
Celon Laboratories
Hetero Drugs
Dr Reddy's Laboratories
Zuventus Healthcare
United Biotech
Panacea Biotec
Cipla
Glenmark Pharmaceuticals
Nobel Ilac Sanayii Ve Ticaret
Accure Labs
Cadila Pharmaceuticals
Ethypharm
Flagship Biotech International
Globela Pharma
Jodas Expoim
Nishchay Pharmaceuticals
Sichuan Xieli Pharmaceutical

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Gefitinib consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Gefitinib market by identifying its various subsegments.
Focuses on the key global Gefitinib manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Gefitinib with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Gefitinib submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.